【环球网财经综合报道】2025年A股IPO市场交出了一份亮眼的成绩单，同时也展现了鲜明的结构性变 化。最新统计数据显示，截至12月22日，年内A股发行上市家数共计106家，同比增长9.28%；募资总额 却高达1190.83亿元，同比激增91.23%。募资增速远超数量增速，直观反映出今年IPO市场"少而精"的特 征——超大型项目的密集落地成为募资规模跳涨的关键动力，这与A股从"规模扩张"向"质量优先"的转 型高度契合。 随着IPO市场的活跃，券商投行格局也迎来重塑。年内共有30家券商斩获A股IPO项目，保荐承销费用合 计60.03亿元，同比增长38.03%。值得注意的是，国泰君安与海通证券合并后的"国泰海通"效应显现， 以17家的保荐数量位居行业第一，超过中信证券。而在募资规模和承销费率方面，头部券商依然展现出 强大优势，中金公司以平均每单47.91亿元的募资额居首，华泰联合则以266.74亿元的实际募资规模排名 榜首。与此同时，大额项目也带来了承销费率的差异化，中金公司、华泰联合等大券商的平均承销费率 相对较低。 监管层面的变化同样值得关注。年内IPO终止审查企业共计107家，同比大幅减少75.34%。终止数 ...

（来源：河北新闻网） 转自：河北新闻网 位于石家庄市国际生物医药园的绿叶嘉奥制药石家庄有限公司，工作人员正在进行设备的调试。 塔吊挥动长臂，厂房拔节生长，运输车辆往来穿梭，实验室里灯火通明……位于石家庄高新区的石家庄市国际生物医药园里，扑面而来的是项 目建设的火热气息与产业集聚的蓬勃活力。 创新沃土蓄发展势能，项目建设现场酣畅淋漓。目前，生物医药园汇聚了300余家企业，初步形成龙头企业引领、中型企业支撑、小微企业蓬 勃发展的良好生态。进入四季度以来，园区正以"冲刺"之姿，全力打好年度收官战，推动更多实验室技术走向生产线，为高质量发展持续注入 新动能。 优质项目串珠成链 绿叶嘉奥是高新区引进生物医药园的一家创新药研发企业，通过"资本运作、基金支持、以投代补"的方式，他们与政府合作共建项目。结合项 目引进和落地建设实际，高新区建立协同高效的项目入区评审和开展项目包联服务，绘制了招商引资项目入区落地流程图，以专家论证会、项 目小组会等形式，严把项目入区关，提高了生物医药园入园项目的质量。 发展活力，来源于一个个项目的扎实推进。 今年以来，高新区共引进生物医药类项目59个，依托生物医药园打造的良好发展环境，让更多企业 ...

Market Overview - U.S. equities have experienced a rebound, particularly in AI-related stocks, following a selloff due to concerns over inflated valuations and high capital expenditures impacting profits [1][11] - Major indexes recorded their fifth consecutive session of gains, with the Dow Jones Industrial Average rising by 288.75 points (0.60%) to 48,731.16, the S&P 500 gaining 22.26 points (0.32%) to 6,932.05, and the Nasdaq Composite increasing by 51.46 points (0.22%) to 23,613.31 [2][11] Economic Indicators - Recent data indicated a resilient economy, with new applications for U.S. jobless benefits unexpectedly falling last week [1][11] - The market is currently pricing in approximately 50 basis points of rate cuts from the Federal Reserve for the next year, although expectations for a January cut are low [1][11] Sector Performance - Financials were among the best-performing sectors in the S&P 500, with a gain of 0.5%, while the energy index was the only sector to close in negative territory [7][11] - Bank stocks contributed to the overall market gains, supporting the bullish sentiment [11] Notable Company Movements - Nike shares increased by 4.6% after Apple CEO Tim Cook purchased approximately $3 million worth of shares [9][11] - Dynavax Technologies surged by 38.2% following an announcement that French drugmaker Sanofi would acquire the company for around $2.2 billion (1.9 billion euros) [10][11] - Intel shares decreased by 0.5% after reports that Nvidia halted tests for manufacturing chips using Intel's 18A production process [9][11] Market Sentiment - The recent gains in U.S. stocks have led to speculation about a "Santa Claus rally," a seasonal trend where the S&P 500 typically posts gains during the last five trading days of the year and the first two in January [7][11] - Wall Street's "fear gauge" remains at levels not seen since December 2024, yet the bull market, which began in October 2022, continues to thrive due to optimism surrounding AI, potential rate cuts, and a resilient economy [9][11]

NEW TAIPEI CITY, Dec. 24, 2025 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint ...

Cantor公司分析师埃里克·施密特表示："这比Pyrukynd(该药物的另一商品名)33.5万美元的批发 采购成本价格略有溢价。我们原本预期是平价定价。" 在实施一项必需的安全计划后，Aqvesme预计将于下个月晚些时候上市。 该药物将附带关于肝细胞损伤的黑框警告，并要求在治疗的前24周内每四周进行一次肝功能检测。 药品标签还将建议肝硬化患者不要使用。 至少有两位分析师表示，药品标签内容和相关要求符合预期。 该公司首席财务官塞西莉亚·琼斯在周三的分析师电话会议上表示，该药物每位患者的年治疗费用 约为42.5万美元。 美国食品药品监督管理局(FDA)批准了Agios Pharmaceuticals(AGIO.US)药物用于治疗某种血液疾病的 扩大适应症，该股股价周三大幅上涨18.63%。 该公司周二晚间宣布，其化学名为米他匹伐(商品名：Aqvesme)的药物获批准，成为针对非输血依 赖性和输血依赖性α或β地中海贫血患者的首个口服疗法。 地中海贫血是一种遗传性血液疾病，影响人体产生血红蛋白和健康红细胞的能力。 该药物(商品名：Pyrukynd)已于2022年获得FDA批准，用于治疗成人丙酮酸激酶缺乏症所致的红 ...

坚决扛好经济大省挑大梁的省会担当 ——市委经济工作会议侧记 □ 南京日报/紫金山新闻记者 以推动科技创新和产业创新融合为主线，着力培育壮大新动能。今年以来，全市获批34家全国重点实验 室，占全省77%，全年科技中小型企业突破2.38万家，加快建设42家概念验证中心、57家中试平台、30 家公共技术服务平台，滚动培育40家高水平新型研发机构。市科技局党组书记、局长赵成军表示，他们 将重点围绕"谋长远、促转化、建平台、育主体、优创新"五个方面抓好科技创新工作，突出科技创新和 产业创新融合，紧盯成果转化需求开展高效对接服务，高标准打造重点转化平台，不断提升重大科创平 台原始创新策源能力，"量质并举"培育科技型企业，营造开放创新生态，力争在国家创新体系中体 现"新地位"、在供给与需求侧双向奔赴中激发"新活力"、在提升创新策源能力上实现"新突破"、在壮大 创新型企业集群上迈上"新台阶"、在营造产业科技创新生态中争取"新优势"。 "稳"的基础更加巩固、"进"的态势持续增强、"新"的动能加速壮大……收官之年的亮眼表现，成为我 市"十四五"以来，面对错综复杂的外部形势和艰巨繁重的改革发展稳定任务，团结奋进、砥砺前行，保 持G ...

至少有两位分析师表示，药品标签内容和相关要求符合预期。 地中海贫血是一种遗传性血液疾病，影响人体产生血红蛋白和健康红细胞的能力。 在实施一项必需的安全计划后，Aqvesme预计将于下个月晚些时候上市。 该药物将附带关于肝细胞损伤的黑框警告，并要求在治疗的前24周内每四周进行一次肝功能检测。药品 标签还将建议肝硬化患者不要使用。 美国食品药品监督管理局(FDA)批准了Agios Pharmaceuticals(AGIO.US)药物用于治疗某种血液疾病的扩 大适应症，该股股价周三大幅上涨18.63%。 该公司周二晚间宣布，其化学名为米他匹伐(商品名：Aqvesme)的药物获批准，成为针对非输血依赖性 和输血依赖性α或β地中海贫血患者的首个口服疗法。 该公司首席财务官塞西莉亚.琼斯在周三的分析师电话会议上表示，该药物每位患者的年治疗费用约为 42.5万美元。 该公司针对的是美国约6000名成人地中海贫血患者群体，其中约4000名患者在药物上市初期即有机会获 得治疗。 此次最新批准是基于一项后期研究，在该研究中，与安慰剂组相比，接受该药物治疗的患者在血红蛋白 反应方面显示出统计学上的显著改善。 Cantor公司分析师 ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

分组1: Bristol Myers Squibb - Bristol Myers Squibb offers an attractive dividend yield of 4.6% with a payout ratio of around 85%, indicating a balance of risk and reward for investors [4][6][12] - The company faces potential patent cliffs, with its cancer drugs Revlimid and Pomalyst facing generic competition in 2026, and cardiovascular drug Eliquis losing patent protections in 2028 [6][4] - Despite these challenges, Bristol Myers Squibb has been investing in its drug pipeline through acquisitions, suggesting a likelihood of sustaining its dividend [6][4] 分组2: Medtronic - Medtronic has a dividend yield of 2.9% and has experienced a slowdown in dividend growth, which has dropped from mid to high single digits to low single digits [8][11] - The company is undergoing a restructuring to refocus on growth, including exiting certain businesses and investing in new products, with a notable spinoff of its diabetes division planned [9][11] - Medtronic has increased its dividend for 48 consecutive years, indicating strong potential for future growth and a payout ratio of around 75%, positioning it well for long-term investors [11][12]

Core Viewpoint - Agios Pharmaceuticals has received FDA approval for mitapivat, a treatment for anemia in adults with alpha or beta thalassemia, which will be marketed as AQVESME in the United States [2]. Group 1: FDA Approval - The FDA has approved mitapivat for treating anemia in adults with alpha or beta thalassemia [2]. - The drug will be marketed under the brand name AQVESME in the United States [2]. Group 2: Investor Relations - Morgan Sanford, Vice President of Investor Relations, is leading the conference call to discuss the approval and its implications [2]. - The company has provided access to presentation slides on its website for investors [2].